Open AccessMilrinone
Author(s) -
Keister D. Mark,
Kittleson Mark D.,
Bonagura John D.,
Pipers Frank S.,
Knauer Kenneth W.
Publication year - 1990
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/j.1939-1676.1990.tb03107.x
Subject(s) - milrinone , medicine , inotrope , heart failure , cardiology , adverse effect , levosimendan , anesthesia
Milrinone, a positive inotropic drug with vasodilating properties, was administered at doses of 0.5 to 1 mg/kg orally twice daily to 29 dogs with moderateto severe congestive heart failure (CHF). Significant echocardiographic improvement in ventricular systolic function was observed after 3 days of administration of milrinone and at the patients' last echocardiographic observation (day 21in 25 subjects, day 7 in 2 subjects, and day 3 in 2 subjects). Echocardiographic shortening fraction at the initial measurement had a median increase of 6.14%( P < 0.001), and for the last observation a 2.83% increase ( P < 0.005). Most patients also showed improvement in their clinical signs as assessed by the veterinarian (72%) and by owner's evaluation (81%). No consistent problem or adverse reaction to milrinone was observed, except for a small number ofclinically manageable ventricular dysrhythmias. Milrinone appears in this trialto be effective for the treatment of advanced CHF in dogs.